LOUIS PHILIPPE BOULET
FIRST VICE PRESIDENT:
SECOND VICE PRESIDENT:
CHIEF EXECUTIVE DIRECTOR:
GIORGIO WALTER CANONICA
IGNACIO J. ANSOTEGUI
Meet the new Interasma's Executive Board
INTERASMA scientific network (INES) is running a internet based survey on "beliefs and behaviours about biological treatments for severe asthma"
GAA-INTERASMA Scientific Network
Dear colleagues, GAA-INTERASMA scientific network (INES) is running an internet based survey on “beliefs and behaviours about biological treatments for severe asthma” which you can access by clicking on the following link:
The survey is anonymous however if you wish to leave your e-mail address you will be part of the communication activities and you will be invited to be part of the INES Network*
GAA-INTERASMA Secretary General
INES (GAA-INTERASMA Scientific network)
* INESnet (GAA-INTERASMA Scientific nertwork) is a meeting place for members to get to know each other, to know who does what and where. The purpose is to create an international network, to work together and offer opportunities. The values which underlie this project are the sharing of efforts, facilities, opportunities, thoughts and ideas with the aim to develop and spread a critical quantity of scientific products, favoring rapidity in full respect of scientific rigor. The drivers for all INESnet members should be to be part of a recognized scientific network and the achievement of benefits from cooperative working. The expected change is the increase of members’ scientific expertise (CV- career) and the opportunity to grow from the professional point of view. INESnet was born as an editorial project on obstructive lung diseases. The startingworking tool will be a dedicated digital platform for meeting, sharing, discussing, researching and writing papers. This will allow to start a tight collaboration characterized by open-mindedness, fluency, speed, productivity on a broad field of issues in obstructive lung diseases.
The following new article have just been published in Asthma Research and Practice: Exhaled biomarkers in childhood asthma: old and new approaches
Asthma is a chronic condition usually characterized by underlying inflammation. The study of asthmatic inflammation is of the utmost importance for both diagnostic and monitoring purposes. The gold standard for investigating airway inflammation is bronchoscopy, with bronchoalveolar lavage and bronchial biopsy, but the invasiveness of such procedures limits their use in children. For this reason, in the last decades there has been a growing interest for the development of noninvasive methods.
In the present review, we describe the most important non-invasive methods for the study of airway inflammation in children, focusing on the measure of the fractional exhaled nitric oxide (feNO), on the measure of the exhaled breath temperature (EBT) and on the analysis of both exhaled breath condensate (EBC) and exhaled air (Volatile Organic Compounds, VOCs), using targeted and untargeted approaches. We summarize what is currently known on the topic of exhaled biomarkers in childhood asthma, with a special emphasis on emerging approaches, underlining the role of exhaled biomarkers in the diagnosis, management and treatment of asthma, and their potential for the development of personalized treatments.
Among non-invasive methods to study asthma, exhaled breath analysis remains one of the most interesting approaches, feNO and “-omic” sciences seem promising for the purpose of characterizing biomarkers of this disease.
The following new articles have just been published in Asthma Research and Practice
|Sewunet Admasu Belachew, Daniel Asfaw Erku, Dawit Kumilachew Yimenu and Begashaw Melaku Gebresillassie|
|Asthma Research and Practice 2018, 4:8 | Published on: 16 July 2018|
|Full Text | PDF|
WCA 2018 - Scientific Advisory Board
Stephen T. Holgate
Peter Le Souef
Johan Christian Virchow
Assessment of predictors for acute asthma attack in asthmatic patients visiting an Ethiopian hospital: are the potential factors still a threat?
Sewunet Admasu Belachew Daniel Asfaw Erku, Dawit Kumilachew Yimenu and Begashaw Melaku Gebresillassie
Recurrent exacerbations in patients with moderate or severe asthma are the major causes of morbidity, mortality and medical expenditure. Identifying predictors of frequent asthma attack might offer the fertile ground of asthma management. However, systematic data on asthma management is scarce in Ethiopia.
The purpose of the present study was to determine predictors of acute asthma attack in patients with asthma attending emergency department of University of Gondar Comprehensive Specialized Hospital (UOGCSH) in Gondar, northwestern Ethiopia.
An institutional-based cross-sectional self-administered survey was conducted on 108 asthmatic patients who came to the emergency department of UOGCSH following acute asthma attack. Data were collected through interviewer administered questionnaire. Logistic regression was done to see the possible association of potential factors that may lead to asthma exacerbation.
About half of the respondents (51.9%) were female and one third of patients (38.9%) were within the age range of between 46 and 60 years. The leading potential predictor were frequent exposure to various ongoing allergen (68.5%) followed by revelation to occupational sensitizers (67.6%). Chronic sinusitis (AOR = 3.532, 95% CL = 1.116–11.178), obstructive sleep apnea (AOR = 3.425, 95% CL = 1.255–9.356) and psychological disfunctioning (3.689 (1.327–10.255)) were among the significantly associated factors of acute asthma exacerbation.
Now days, the backbone for long-term asthma management is to prevent exacerbations. Chronic sinusitis, obstructed sleep apnea and psychosocial dysfunction were originated to be considerably linked with repeated exacerbations of asthma. Among those significantly associated predictors, obstructed sleep apnea were the most prevalent one.
World Congress of Asthma - October 3-6, 2018, Tokyo, Japan / Abstract
Following the request from several participants we have the pleasure and honor to inform you that the deadline for submission of abstracts has been extended until June 30, 2018. The early bird fee is therefore also extended until June 30, 2018.
Deadline to submit an abstract for the XXIV World Congress of Asthma in Tokyo, Japan, October 3-6, 2018, expires on Friday, June 8
The deadline to electronically submit an abstract for the XXIV World Congress of Asthma in Tokyo, Japan, October 3-6, 2018, expires on Friday, June 8, so you still have the opportunity to take advantage of the Early Bird Registration fee.
To Submit your Abstract please click HERE
To Register please click HERE
Your data privacy and communication preferences are a top priority for us so in order to comply with GDPR consent requirements, we need to know that you would still like to receive content in relation to Global Asthma Association - Interasma and its World Congress of Asthma.
We will only contact you with useful information in relation to and on behalf of the GAA-Interasma Board and the Organizing & Scientific Committees of WCAs.
If you prefer to be opted out of all communications, please click the Unsubscribe link below.
Asthma Research and Practice: Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms
The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient.
Twenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity. Patients measured and recorded PEF every morning and evening in their asthma diary along with their symptoms and the dose of drugs taken.
Sixteen of the 28 patients increased their dose for asthma symptoms. The time to recovery from the asthma symptoms was significantly shorter when cough was the only symptom present compared with dyspnea or wheeze (1.4 vs. 5.3 or 6.6 days, p < 0.05) and when they had only one symptom compared with two or three symptoms (1.3 vs. 5.7 or 10.5, p < 0.01). The relationship between PEF (% of personal best) when the dose was increased (Y) and the days for the increased dose to achieve a PEF greater than PEF in the symptom-free state (X) was determined to be Y = − 0.591X + 89.2 (r2 = 0.299, p < 0.001).
As a guide for increasing the BFC dose when patients with mild asthma have asthma symptoms, the dose should be increased when cough is present or PEF is decreased to 88.9% (i.e., X = 0.5).